Pharmaguy's Insights Into Drug Industry News
186.1K views | +3 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

Fastest Selling Drugs in First Half of 2016

Fastest Selling Drugs in First Half of 2016 | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Recently-published second-quarter results provide an opportunity to assess which pharmaceutical products have grown the most during the first half of 2016 versus the same period last year.

Sales of Bristol-Myers Squibb's PD-1 inhibitor Opdivo lead the way, with global revenues of $1.5 billion generated during the first six months of 2016 versus sales of just $162 million in the comparative period of 2015.

Opdivo is approved across a number of oncology indications, with performance in the second-line non-small-cell lung cancer (NSCLC) market integral to its impressive launch. Revenue growth over the next six to 12 months will be watched with great interest, however, following Opdivo's recent failure to demonstrate a survival benefit in first-line patients; an indication where Merck & Co.'s rival drug Keytruda is now expected to assume first-to-market status.

Pharma Guy's insight:

Compare this to Thomson Reuters' Drugs to Watch report; http://sco.lt/6gP3J3 

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Top 20 in 2020 - Worldwide Drug Sales Estimate

Top 20 in 2020 - Worldwide Drug Sales Estimate | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Forecasting drug sales is a tricky business; just ask any biopharma CEO who has overpromised and underdelivered. The people who make it their business know that very well, and they update their numbers with every big shift in the market and every surprise result from a key clinical trial.

These days, the variables are many, with some more variable than others. Biosimilars are coming in the U.S., with several big products targeted in the next few years. We know that's going to hit the original biologics; we aren't sure how much. Payers are increasingly pressing for discounts, particularly in highly competitive fields like hepatitis C drugs, respiratory meds and diabetes treatments. How much will those discounts grow, and how much might the pressure spread beyond those areas?

Pharma Guy's insight:

See "World Preview 2015, Outlook to 2020" for details; http://bit.ly/2020v2015DrugSales 

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

10 Essential Facts About Medicare and Prescription Drug Spending

10 Essential Facts About Medicare and Prescription Drug Spending | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Prescription drugs play an important role in medical care for 57 million seniors and people with disabilities, and account for $1 out of every $6 in Medicare spending. The majority of Medicare prescription drug spending is for drugs covered under the Part D prescription drug benefit, administered by private stand-alone drug plans and Medicare Advantage drug plans. Medicare Part B also covers drugs that are administered to patients in physician offices and other outpatient settings.

After a period of relatively slow growth, total and per capita Part D spending has increased more rapidly in the past few years mainly due to treatments for Hepatitis C, and is projected to increase more rapidly in the next decade as more high-priced specialty drugs become available, according to the recently-released annual report of the Medicare Boards of Trustees.

Even with Medicare’s prescription drug coverage, beneficiaries can face substantial out-of-pocket costs, particularly if they use specialty drugs or multiple high-cost brand-name drugs. The following series of graphics examines trends in Medicare spending on prescription drugs, how Medicare coverage affects beneficiary access and costs, and what the public thinks about different options for keeping drug costs down.

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

2015 Will See More Blockbuster Drugs Than Ever

2015 Will See More Blockbuster Drugs Than Ever | Pharmaguy's Insights Into Drug Industry News | Scoop.it

The Intellectual Property and Science business of Thomson Reuters, the world’s leader in intelligent information for businesses and professionals, today released the 2015 edition of its annual Drugs to Watch report. The study reveals a significant increase in the number of expected blockbusters from three drugs in 2014 to eleven in 2015. Three of the new drugs are expected to reach over $3 billion in sales by 2019. 

more...
No comment yet.